BioSpace News Archive

The event took place on October 24 at the Intercontinental Hotel in Frankfurt, Germany.

Former Pfizer executive joins AZTherapies.

This acquisition provides a more comprehensive service offering and a platform for growth for Sterigenics’ Nelson Labs business.

Medicure has acquired an exclusive license to sell and market PREXXARTAN (valsartan) oral solution in the U.S. and its territories from Carme for a seven year term with extensions to the term available.

Nektar Therapeutics will announce its financial results for the third quarter ended September 30, 2017, on Tuesday, November 7, 2017, after the close of U.S.based financial markets.

Under terms of the agreement, Medicure obtains exclusive rights in the United States and territories to develop, manufacture and market PREXXARTAN for a seven year term, with potential extensions to the term available.

Citius’ investigational program for Mino-Lok is designated “Fast Track” and is currently starting up sites for a phase III trial of Mino-Lok in the U.S.

Soligenix announced that it has entered into definitive agreements with investors for the purchase and sale of 1,575,500 shares of common stock at a price of $2.00 per share in a registered direct offering and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement.

Medizone today announced the appointment of Philip A. Theodore, as its Executive VP-Operations and Administration, General Counsel and Corporate Secretary.

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (“VEGFR”) 1, 2 and 3.